Krebs Biochemicals & Industries Limited concluded its 34th Annual General Meeting on September 29, 2026, with all five ordinary resolutions passed by requisite majority. The meeting, held via Video Conferencing, covered FY26 financial adoption, director reappointments, and related party transaction approvals.

Voting results and scrutiny

The scrutinizer’s report confirmed that 156.78 lakh votes were polled across the resolutions. For the adoption of audited financial statements (Resolution 1), promoters and promoter group cast 1.57 crore votes in favour, representing 99.87% of their holding. Public non-institutional shareholders recorded a minor dissent of 213 votes (1.51% of votes polled by this category), but the resolution passed comfortably with 99.99% total support.

Director reappointments for Dr. R T Ravi and Mr. Manish Kumar Jain also secured overwhelming backing. In both cases, promoter group votes were unanimous in favour. Public non-institutional dissent remained marginal, ranging between 1.50% and 3.41% of votes polled by that specific category, ensuring passage of both resolutions.

Related party transactions and auditor remuneration

Approval for related party transactions with Ipcia Laboratories Limited (Resolution 4) was notable for the exclusion of promoter votes, as the promoter group was interested in the agenda. Consequently, only public shareholders voted on this item. The resolution received 6,097 votes in favour against 216 votes against, resulting in a 96.58% approval rate among participating public shareholders.

The ratification of cost auditor remuneration (Resolution 5) saw similar patterns to the financials adoption, with promoters voting unanimously in favour and public non-institutional dissent at 1.53% of their polled votes.

Meeting attendance and process

Electronic voting facilities were provided from September 25 to September 28, 2026. Ms. Kritika Sharma, Practicing Company Secretary, served as the Scrutinizer. The results were declared after the receipt of her report.

Attendance data revealed that while no shareholders attended physically or through proxy, 43 members participated via video conferencing: 3 from the promoter group and 40 from the public. The meeting commenced at 11:30 am and concluded at 12:15 pm.

Citurgia Biochemicals Limited attributed the delayed disclosure of its Registrar of Companies (ROC) approval for an AGM extension to internal communication lapses and confirmation delays. The company missed the 24-hour timeline mandated by SEBI regulations after receiving approval on September 18, 2026, to hold its meeting by October 31, 2026.

The management stated it erroneously believed the disclosure would occur automatically upon receipt of the ROC permission. The company has since strengthened its internal reporting mechanisms to ensure future compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Approval Details

The ROC, Mumbai, granted a one-month extension under Section 96(1) of the Companies Act, 2013. This allows Citurgia to convene its 51st Annual General Meeting for the financial year ended March 31, 2026, by October 31, 2026. The original statutory deadline was September 30, 2026.

Disclosure Timeline and Explanation

Citurgia initially sought a three-month extension until December 31, 2025, via a board resolution dated August 31, 2026. The ROC approved only a one-month extension in its letter dated September 18, 2026. The material event occurred on August 31, 2026, but the company failed to inform BSE Limited within the prescribed period due to inadvertent error.

Kashi Nath, Whole Time Director, signed the explanation letter submitted to BSE on September 25, 2026. He confirmed that the delay was not intentional and requested the exchange to condone the lapse. The company reiterated that the specific date of the AGM will be intimated within the extended timeline.

Compliance Advisory

In its order, the ROC advised Citurgia to ensure careful compliance with the provisions of the Companies Act, 2013, in future filings. The regulatory body noted that while the extension was granted, strict adherence to statutory timelines is critical for corporate governance standards.